IL6 and rheumatoid arthritis: After 6-month treatment, reduction of disease activity score (DAS28-ESR) and swollen joint count was more significant in tocilizumab-treated patients than in abatacept-treated patients, suggesting that IL-6-directed therapy might be a more logical and effective treatment choice than T cell costimulation blockade in RA patients with failed rituximab therapy (293).